Transcept Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011

Date: March 1, 2011
Pages: 52
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: TECAD6D994DEN
Leaflet:

Download PDF Leaflet

Transcept Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Transcept Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Transcept Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Transcept Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Transcept Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Transcept Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Transcept Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Transcept Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Transcept Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Transcept Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Transcept Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Table of Contents
List of Tables
List of Figures
Transcept Pharmaceuticals, Inc. Snapshot
Transcept Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Transcept Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Transcept Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Transcept Pharmaceuticals, Inc. – Pipeline Products Glance
Transcept Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Transcept Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Transcept Pharmaceuticals, Inc. – Drug Profiles
Intermezzo
Product Description
Mechanism of Action
R&D Progress
Asentar + Taxotere
Product Description
Mechanism of Action
R&D Progress
AQ4N
Product Description
Mechanism of Action
R&D Progress
AQ4N + Temozolomide + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Asentar
Product Description
Mechanism of Action
R&D Progress
TO-2061
Product Description
Mechanism of Action
R&D Progress
AQ4N
Product Description
Mechanism of Action
R&D Progress
Transcept Pharmaceuticals, Inc. – Pipeline Analysis
Transcept Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Transcept Pharmaceuticals, Inc. - Pipeline Products By Target
Transcept Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Transcept Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Transcept Pharmaceuticals, Inc. – Recent Pipeline Updates
Transcept Pharmaceuticals, Inc. - Dormant Projects
Transcept Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Asentar
Transcept Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 19, 2010: Transcept Announces Preliminary Results From Intermezzo Highway Driving Study
Mar 25, 2010: Transcept Updates Plan For Intermezzo NDA Resubmission Following Teleconference With FDA
Mar 25, 2010: Transcept Updates Plan For Intermezzo NDA Resubmission Following Teleconference With FDA
Mar 24, 2010: Transcept Receives Second US Patent Covering Intermezzo Formulation
Mar 24, 2010: Transcept Receives Second US Patent Covering Intermezzo Formulation
Feb 09, 2010: Transcept Pharmaceuticals Granted US Patent Covering Intermezzo Formulation
Nov 23, 2009: Transcept Pharmaceuticals Schedules To Meet With FDA To Discuss Intermezzo Complete Response Letter
Nov 04, 2009: Transcept Pharmaceuticals Receives Notice Of Allowance For U.S. Patent Application On Intermezzo
Oct 29, 2009: Transcept Pharmaceuticals Receives Complete Response Letter From FDA On Intermezzo New Drug Application
Jun 11, 2009: Transcept Pharmaceuticals Announces Expected FDA Extension Of Regulatory Review Period For Intermezzo
Financial Deals Landscape
Transcept Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011
Transcept Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011
Transcept Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Transcept Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Transcept Pharmaceuticals Secures $23 Million In Series C Financing
Equity Offering
Novacea Completes Private Placement Of $12 Million
Licensing Agreements
Purdue Pharma Enters Into License Agreement With Transcept Pharmaceuticals
Novacea Enters Into Licensing Agreement With Schering-Plough For Asentar
BTG Enters Into License Agreement With Novacea For AQ4N
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Transcept Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Transcept Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Transcept Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Transcept Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2011
Transcept Pharmaceuticals, Inc. – Filed, 2011
Transcept Pharmaceuticals, Inc. – Phase III, 2011
Transcept Pharmaceuticals, Inc. - Phase II, 2011
Transcept Pharmaceuticals, Inc. - Phase I, 2011
Transcept Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2011
Transcept Pharmaceuticals, Inc. - Pipeline By Target, 2011
Transcept Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Transcept Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011
Transcept Pharmaceuticals, Inc. – Recent Pipeline Updates, 2011
Transcept Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Transcept Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Transcept Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Transcept Pharmaceuticals, Inc., Deals Summary by Region, 2004 to YTD 2011
Transcept Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011

LIST OF FIGURES

Transcept Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Transcept Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Transcept Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Transcept Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2011
Transcept Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2011
Transcept Pharmaceuticals, Inc. - Pipeline By Target, 2011
Transcept Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Transcept Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011

Ask Your Question

Transcept Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: